Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (18)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Jayasena, S. D.
Right arrow Articles by Woolfson, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jayasena, S. D.
Right arrow Articles by Woolfson, R. G.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2001) 16: 1681-1685
© 2001 European Renal Association-European Dialysis and Transplant Association

Outcome in patients with end-stage renal disease following heart or heart–lung transplantation receiving peritoneal dialysis

Shyama D. Jayasena, Ahmad Riaz, Christina M. Lewis, Guy H. Neild, F. Derek Thompson and Robin G. Woolfson

Department of Nephrology, Middlesex Hospital, UCLH Trust, London, UK

Background. End-stage renal disease (ESRD) complicates 5–10% of heart and heart–lung transplant patients. We report our experience of peritoneal dialysis (PD) in 17 such patients.

Methods. Between March 1995 and February 1999, 13 heart transplant and four heart–lung transplant patients (11 male, 6 female) joined our PD programme (10 continuous ambulatory PD, seven automated PD). Median time from heart or heart–lung transplantation to ESRD was 9 years (range 1–13 years), and median age at introduction of renal replacement therapy was 51 years (range 23–66 years). The frequency of exit-site infections, peritonitis, and PD survival (including technique failure and death) in the transplant group (TxP) was calculated retrospectively. These were compared with two contemporary control groups: PD patients immunosuppressed for other indications (ISP, n=19) and, all other patients recruited onto the PD programme (NISP, n=132).

Results. Median follow-up was 10 months (range 2–27 months) for TxP, 7 months (range 2–29 months) for ISP, and 14 months (range 1–48 months) for NISP groups. The frequency of exit-site infections was similar in each group: 1 in 26 months for TxP; 1 in 30 months for ISP, and 1 in 27 months for NISP (P=NS). The frequency of peritonitis was greater in the TxP group at 1 in 15 months, compared with 1 in 20 months for ISP and 1 in 29 months for NISP (TxP vs NISP, P<0.05). PD failure following infection was 23.5% for TxP, 10.5% for ISP, and 12.9% for NISP. Actuarial PD survival at 24 months was only 25.2% in the TxP group compared with 79% in the NISP group. There were no deaths related to immediate complications of PD.

Conclusions. Increased risk of PD peritonitis and reduced PD survival is reported in this cohort of 17 heart and heart–lung recipients with ESRD. Nevertheless, for patients with severely impaired cardiac function, PD may still offer therapeutic advantage.

Keywords: cardiac function; end-stage renal disease; exit-site infection; heart; heart-lung transplantation; peritoneal dialysis; peritonitis

Correspondence and offprint requests to: Dr R. G. Woolfson, Department of Nephrology, Middlesex Hospital, Mortimer Street, London W1N 8AA, UK.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Am. Soc. Nephrol.Home page
R. D. Bloom and P. P. Reese
Chronic Kidney Disease after Nonrenal Solid-Organ Transplantation
J. Am. Soc. Nephrol., December 1, 2007; 18(12): 3031 - 3041.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
E. Villar, P. Boissonnat, L. Sebbag, A. Hendawy, R. Cahen, P. Trolliet, M. Labeeuw, R. Ecochard, and C. Pouteil-Noble
Poor prognosis of heart transplant patients with end-stage renal failure
Nephrol. Dial. Transplant., May 1, 2007; 22(5): 1383 - 1389.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
R. R. Smith, J. Wray, A. Khaghani, and M. Yacoub
Ten year survival after paediatric heart transplantation: a single centre experience
Eur. J. Cardiothorac. Surg., May 1, 2005; 27(5): 790 - 794.
[Abstract] [Full Text] [PDF]


Home page
Ann. Thorac. Surg.Home page
J. Groetzner, B. Reichart, U. Roemer, S. Reichel, R. Kozlik-Feldmann, A. Tiete, J. Sachweh, H. Netz, and S. Daebritz
Cardiac Transplantation in Pediatric Patients: Fifteen-Year Experience of a Single Center
Ann. Thorac. Surg., January 1, 2005; 79(1): 53 - 60.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
A. K. Khanna, M. S. Plummer, G. Hilton, G. M. Pieper, and S. Ledbetter
Anti-Transforming Growth Factor Antibody at Low but Not High Doses Limits Cyclosporine-Mediated Nephrotoxicity Without Altering Rat Cardiac Allograft Survival: Potential of Therapeutic Applications
Circulation, December 21, 2004; 110(25): 3822 - 3829.
[Abstract] [Full Text] [PDF]


Home page
Eur. J. Cardiothorac. Surg.Home page
J. Groetzner, I. Kaczmarek, P. Landwehr, M. Mueller, S. Daebritz, P. Lamm, B. Meiser, and B. Reichart
Renal recovery after conversion to a calcineurin inhibitor-free immunosuppression in late cardiac transplant recipients
Eur. J. Cardiothorac. Surg., March 1, 2004; 25(3): 333 - 341.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.